

Ogawa, Katelyn

From: Richard A. Van Etten, MD, PhD, Director, Chao Family Comprehensive Cancer Center
<hsmarcom@uci.edu>
Sent: Tuesday, April 19, 2022 7:00 AM
To: Ogawa, Katelyn
Subject: Cancer clinical trials open to patients

UCI Health

Chao Family
Comprehensive Cancer Center

Cancer Clinical Trials

The UCI Health Chao Family Comprehensive Cancer Center is now enrolling patients in these featured clinical trials.

To refer a patient or get more information about a clinical trial, click on the principal investigator's name to send an email. You may also contact us at ucstudy@uci.edu or [877-UC-Study](tel:877-UC-Study). To search all cancer clinical trials now available at UCI Health, visit cancer.uci.edu/clinical-trials-flowcharts

Brain and nervous system

A phase 2 trial of the immune checkpoint inhibitor nivolumab in patients with recurrent select rare central nervous system (CNS) cancers (UCI-20-152/17C0102 C)

For more information, contact principal investigator Daniela Bota, MD

A phase 2 study of the PARP inhibitor olaparib (AZD2281) in IDH1 and IDH2 mutant, advanced solid tumors (ETCTN-10129)

For more information, contact principal investigator Xiao-Tang Kong, MD

Breast

A phase 2 trial of radium-223 dichloride in combination with paclitaxel in patients with metastatic breast cancer that has spread to the bones (ETCTN-10302)

For more information, contact principal investigator Ritesh Parajuli, MD

A phase 3 clinical trial evaluating de-escalation of breast radiation for conservative treatment of stage I, hormone-sensitive, HER2-negative breast cancer with an oncotype

recurrence score of less than or equal to 18 (DEBRA) (NRG-B007)

For more information, contact principal investigator Rita Mehta, MD

Gastrointestinal

A phase 2, randomized study of de-intensified chemoradiation for early-stage anal squamous cell carcinoma (DECREASE) (EA2182)

For more information, contact principal investigator Jason Zell, DO

A phase 1b/2 study of agents targeting the mitogen-activated protein kinase pathway in patients with advanced gastrointestinal malignancies (HERKULES-3) (UCI-21-110/ERA-007-03)

For more information, contact principal investigator Farshid Dayyani, MD

Genitourinary

A phase 2 study of olaparib (AZD2281) in patients with metastatic/advanced urothelial carcinoma with DNA-repair defects (ETCTN-10144)

For more information, contact principal investigator Arash Rezazadeh Kalebasty, MD

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (UCI 18-138/SGN22E-002)

For more information, contact principal investigator Nataliya Mar, MD

An open-label study of androgen receptor inhibition with darolutamide plus androgen deprivation therapy (ADT) vs. ADT in men with metastatic, hormone-sensitive prostate cancer using an external control arm (ARASEC) (UCI-21-130/21516)

For more information, contact principal investigator Edward Uchio, MD

Gynecologic oncology

A phase 2 study of tazemetostat (EPZ-6438) in recurrent or persistent endometrioid or clear cell carcinoma of the ovary and recurrent or persistent endometrioid endometrial adenocarcinoma (NRG-GY014)

For more information, contact principal investigator Fabio Cappuccini, MD

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant, recurrent

ovarian cancer (GOG-3059)

For more information, contact principal investigator Fabio Cappuccini, MD

Head and neck

A randomized phase 2/3 trial of adjuvant radiation therapy with cisplatin, docetaxel-cetuximab or cisplatin-atezolizumab in pathologic, high-risk squamous cell cancer of the head and neck (RTOG-1216)

For more information, contact principal investigator Rupali Nabar, MD

Randomized phase 2 and phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) (HN001)

For more information, contact principal investigator Rupali Nabar, MD

Hematologic malignancies

The PRIME trial: PARP inhibition in IDH mutant effectiveness trial. A phase 2 study of olaparib in isocitrate dehydrogenase (IDH) mutant, relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome (ETCTN-10264)

For more information, contact principal investigator Deepa Jeyakumar, MD

A phase 3, randomized, placebo-controlled, double-blind study of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in patients receiving chemotherapy for treatment of non-small cell lung cancer (NSCLC), ovarian cancer or breast cancer (UCI-20-128/20170770)

For more information, contact principal investigator Zahra Pakbaz, MD

Hepatobiliary

A randomized phase 2 study of gemcitabine and nab-paclitaxel vs. 5-fluorouracil, leucovorin and liposomal irinotecan in older patients with treatment naïve metastatic pancreatic cancer (GIANT) (EA2186)

For more information, contact principal investigator Jennifer Valerin, MD

A phase 1/2 study of M3814 (peposertib) in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma (ETCTN-10366)

For more information, contact principal investigator Farshid Dayyani, MD

Lung

A randomized, open-label phase 3 study of combination amivantamab and carboplatin-pemetrexed therapy vs. carboplatin-pemetrexed therapy alone in patients with advanced or metastatic non-small cell lung cancer characterized by epidermal growth factor receptor (EGFR) exon 20 insertions (PAPILLON) (UCI-20-102/61186372NSC3001)

For more information, contact principal investigator Misako Nagasaka, MD

A phase 3, randomized study of amivantamb and lazertinib combination therapy vs. osimertinib or lazertinib as first-line treatment in patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (MARIPOSA) (UCI-20-92/73841937NSC3003)

For more information, contact principal investigator Sai-Hong Ou, MD

Skin

A phase 1/2 study of dabrafenib, trametinib, and navitoclax in BRAF-mutant melanoma (phase 1 and 2) and other solid tumors (phase 1 only) (ETCTN-9466)

For more information, contact principal investigator Justin Moyers, MD

A phase 1/2, first-in-human, multipart, open-label, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of DF6002 as a monotherapy and in combination with nivolumab in patients with locally advanced or metastatic solid tumor and expansion in selected indications (UCI-21-40/DF6002-001)

For more information, contact principal investigator Jennifer Valerin, MD



As an NCI-designated comprehensive cancer center, the UCI Chao Family Comprehensive Cancer Center conducts many clinical trials. By participating in a clinical trial, your patients have access to leading-edge treatments and therapies long before they are available to the general public. According to the National Comprehensive Cancer Network (NCCN) guidelines, the best management for any cancer patient is on a clinical trial.

UCI Health | Chao Family Comprehensive Cancer Center | 

UCI Medical Center | 101 The City Drive South | Orange, CA 92868

